Stryker ROA 2006-2018 | SYK
Current and historical return on assets (ROA) values for Stryker (SYK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Stryker ROA for the three months ending June 30, 2018 was 12.05%.
| Stryker Annual ROA | |
|---|---|
| 2017 | 4.60 |
| 2016 | 8.06 |
| 2015 | 8.87 |
| 2014 | 2.98 |
| 2013 | 6.39 |
| 2012 | 9.83 |
| 2011 | 11.07 |
| 2010 | 11.68 |
| 2009 | 12.20 |
| 2008 | 15.10 |
| 2007 | 13.42 |
| 2006 | 13.13 |
| 2005 | 12.67 |
| Stryker Quarterly ROA | |
|---|---|
| Q2 2018 | 2.10 |
| Q1 2018 | 2.00 |
| Q4 2017 | -1.12 |
| Q3 2017 | 2.02 |
| Q2 2017 | 1.84 |
| Q1 2017 | 2.16 |
| Q4 2016 | 2.50 |
| Q3 2016 | 1.76 |
| Q2 2016 | 1.85 |
| Q1 2016 | 2.04 |
| Q4 2015 | 3.22 |
| Q3 2015 | 1.89 |
| Q2 2015 | 2.33 |
| Q1 2015 | 1.35 |
| Q4 2014 | 1.51 |
| Q3 2014 | 0.33 |
| Q2 2014 | 0.74 |
| Q1 2014 | 0.43 |
| Q4 2013 | 2.45 |
| Q3 2013 | 0.69 |
| Q2 2013 | 1.48 |
| Q1 2013 | 2.16 |
| Q4 2012 | 2.05 |
| Q3 2012 | 2.76 |
| Q2 2012 | 2.65 |
| Q1 2012 | 2.81 |
| Q4 2011 | 3.30 |
| Q3 2011 | 2.71 |
| Q2 2011 | 2.67 |
| Q1 2011 | 2.73 |
| Q4 2010 | 2.71 |
| Q3 2010 | 3.13 |
| Q2 2010 | 3.17 |
| Q1 2010 | 3.19 |
| Q4 2009 | 3.37 |
| Q3 2009 | 2.71 |
| Q2 2009 | 3.68 |
| Q1 2009 | 3.71 |
| Q4 2008 | 3.65 |
| Q3 2008 | 3.62 |
| Q2 2008 | 3.81 |
| Q1 2008 | 3.75 |
| Q4 2007 | 3.75 |
| Q3 2007 | 3.34 |
| Q2 2007 | 3.74 |
| Q1 2007 | 3.98 |
| Q4 2006 | 3.83 |
| Q3 2006 | 3.46 |
| Q2 2006 | 4.15 |
| Q1 2006 | 2.95 |
| Q4 2005 | 3.35 |
| Q3 2005 | 2.75 |
| Q2 2005 | 4.27 |
| Q1 2005 | 4.10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $64.899B | $12.444B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $130.270B | 19.97 |
| Abbott Laboratories (ABT) | United States | $120.171B | 25.18 |
| Boston Scientific (BSX) | United States | $51.846B | 26.97 |
| Baxter (BAX) | United States | $41.480B | 28.23 |
| Zimmer Biomet Holdings (ZBH) | United States | $26.421B | 16.97 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.200B | 0.00 |
| ResMed (RMD) | United States | $16.068B | 31.90 |
| Canopy Growth (CGC) | Canada | $11.278B | 0.00 |
| Perrigo (PRGO) | Ireland | $10.034B | 14.24 |
| Bio-Rad Laboratories (BIO) | United States | $8.905B | 57.18 |
| Hill-Rom Holdings (HRC) | United States | $6.097B | 20.68 |
| Insulet (PODD) | United States | $6.090B | 0.00 |
| Haemonetics (HAE) | United States | $5.674B | 51.78 |
| ICU Medical (ICUI) | United States | $5.462B | 37.01 |
| Neogen (NEOG) | United States | $4.728B | 75.23 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.267B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $4.204B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.776B | 0.00 |
| NuVasive (NUVA) | United States | $3.601B | 34.16 |
| National Vision Holdings (EYE) | United States | $3.257B | 71.93 |
| Quidel (QDEL) | United States | $2.673B | 54.77 |
| NxStage Medical (NXTM) | United States | $1.849B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.722B | 24.51 |
| Cardiovascular Systems (CSII) | United States | $1.264B | 754.60 |
| AtriCure (ATRC) | United States | $1.253B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.144B | 18.69 |
| Omeros (OMER) | United States | $1.141B | 0.00 |
| Owens & Minor (OMI) | United States | $1.069B | 11.43 |
| PetIQ (PETQ) | United States | $1.026B | 33.57 |
| Eagle Pharmaceuticals (EGRX) | United States | $1.019B | 30.08 |
| Surmodics (SRDX) | United States | $1.000B | 120.81 |
| Cerus (CERS) | United States | $0.978B | 0.00 |
| MacroGenics (MGNX) | United States | $0.966B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.949B | 62.08 |
| TG Therapeutics (TGTX) | United States | $0.741B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.678B | 32.50 |
| Insys Therapeutics (INSY) | United States | $0.676B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.634B | 21.67 |
| Lantheus Holdings (LNTH) | United States | $0.617B | 19.17 |
| NanoString Technologies (NSTG) | United States | $0.506B | 0.00 |
| Evolus (EOLS) | United States | $0.504B | 0.00 |
| Quanterix (QTRX) | United States | $0.412B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.407B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.353B | 22.73 |
| Surface Oncology (SURF) | United States | $0.320B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.286B | 0.00 |
| Bovie Medical (BVX) | United States | $0.241B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.217B | 0.00 |
| Chimerix (CMRX) | United States | $0.183B | 0.00 |
| Fonar (FONR) | United States | $0.156B | 7.76 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.142B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.136B | 0.00 |
| Female Health (VERU) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.082B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.081B | 24.13 |
| United-Guardian (UG) | United States | $0.077B | 16.87 |
| Neurotrope (NTRP) | United States | $0.068B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.065B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.060B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.042B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.034B | 0.00 |
| Myomo (MYO) | United States | $0.027B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.024B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.023B | 0.00 |
| Senestech (SNES) | United States | $0.016B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.015B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
